Kura Oncology, Inc. (KURA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 25M 50M 75M FY23: 0 FY24: 53.9M FY25: 67.5M FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY10: -20.5K FY11: -23.4K FY12: -22.3K FY13: -22.7K FY14: -23.9K FY22: -139.9M FY23: -165.8M FY24: -193.2M FY25: -303.6M FY10 FY11 FY12 FY13 FY14 FY22 FY23 FY24 FY25

Net Income Annual

-300M -200M -100M 0 100M 200M 300M FY07: -15K FY08: -33.6K FY09: -20K FY10: -22.4K FY11: -27K FY12: -27.3K FY13: -28.6K FY14: -30.7K FY15: -22.6M FY16: -27.6M FY17: -35.4M FY18: -60.4M FY19: -63.1M FY20: -89.6M FY21: -130.5M FY22: -135.8M FY23: -152.6M FY24: -174M FY25: -278.7M FY07 FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-150M -100M -50M 0 50M 100M 150M FY10: -19.2K FY11: -22.7K FY12: -24.4K FY13: -23.2K FY14: -16K FY15: -17.9M FY16: -25.3M FY17: -28.4M FY18: -48.7M FY19: -54.8M FY20: -69.8M FY21: -104.6M FY22: -110.1M FY23: -124.8M FY24: 134.3M FY25: -64.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-150M -100M -50M 0 50M 100M 150M FY15: -18M FY20: -72M FY21: -105.7M FY22: -110.7M FY23: -125M FY24: 133.8M FY25: -70.7M FY15 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY20: 53.1M FY21: 66.4M FY22: 67M FY23: 73.2M FY24: 86.2M FY25: 87.7M FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '10: 0.00 Q1 '11: 0.00 Q2 '11: 0.00 Q3 '11: 0.00 Q4 '11: -0.01 Q1 '12: -0.01 Q2 '12: -0.01 Q3 '12: -0.01 Q4 '12: -0.01 Q1 '13: -0.01 Q2 '13: -0.01 Q3 '13: -0.01 Q4 '13: -0.01 Q1 '14: -0.01 Q2 '14: -0.01 Q3 '14: -0.01 Q4 '14: 0.96 Q1 '15: -0.45 Q2 '15: -0.99 Q3 '15: -1.56 Q4 '15: -2.82 Q1 '16: -1.77 Q2 '16: -1.59 Q3 '16: -1.39 Q4 '16: -1.47 Q1 '17: -1.50 Q2 '17: -1.54 Q3 '17: -1.55 Q4 '17: -1.53 Q1 '18: -1.60 Q2 '18: -1.65 Q3 '18: -1.67 Q4 '18: -1.73 Q1 '19: -1.64 Q2 '19: -1.57 Q3 '19: -1.53 Q4 '19: -1.50 Q1 '20: -1.55 Q2 '20: -1.57 Q3 '20: -1.63 Q4 '20: -1.69 Q1 '21: -1.73 Q2 '21: -1.84 Q3 '21: -1.92 Q4 '21: -1.97 Q1 '22: -2.00 Q2 '22: -2.01 Q3 '22: -2.04 Q4 '22: -2.03 Q1 '23: -2.04 Q2 '23: -2.05 Q3 '23: -2.02 Q4 '23: -2.08 Q1 '24: -2.17 Q2 '24: -2.23 Q3 '24: -2.36 Q4 '24: -2.03 Q1 '25: -2.10 Q2 '25: -2.26 Q3 '25: -2.48 Q4 '25: -3.18 Q1 '26: -3.35 Q2 '26: -3.37 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.